Archivos de Bronconeumología

Our medical research library holds 17 studies published in Archivos de Bronconeumología (2012–2025). Each entry links to the study's record on PubMed and, where there is one, to the publisher's page and a free full text. 7 have an abstract, the authors' own summary as PubMed records it: open "Abstract" to read it. For 3 studies PubMed has no abstract for, we give the abstract printed in the article or, where there is none, a summary we wrote from it, each labeled as such.

About the journal

• Publisher: Elsevier España
• Published: 1964 to the present, Spain
• Language: Spanish
• ISSN: 0300-2896 (print), 1579-2129 (electronic)
• Merged from: Archivos de Bronconeumología
• Its record in the NLM Catalog

2020s

• Sex-Differences in Alpha-1 Antitrypsin Deficiency: Data From the EARCO Registry. H. Ersöz, M. Torres-Durán, A.M. Turner, et al. 2025;61(1):22-30. In English, Spanish. PubMed · Publisher

  Abstract

  Background: Sex and gender influence many aspects of chronic obstructive pulmonary disease (COPD). Limited data are available on this topic in alpha-1 antitrypsin deficiency (AATD). We therefore aimed to investigate sex issues in the EARCO registry, a prospective, international, observational cohort study.

  Methods: Baseline data from PiZZ individuals, enrolled in the registry with complete data on sex and smoking history were analysed by group comparisons and binary logistic regression analyses.

  Results: 1283 patients with AATD, 49.3% women were analysed. Females reported less tobacco consumption (16.8±12.2 vs. 19.6±14.5 PY, p=0.006), occupational exposures towards gases, dusts or asbestos (p<0.005 each) and consumed less alcohol (5.5±7.6 vs. 8.4±10.3u/week, p<0.001). Females reported COPD (41% vs. 57%, p<0.001) and liver disease (11% vs. 20%, p<0.001) less often. However, they had a higher prevalence of bronchiectasis (24% vs. 13%, p<0.001). Despite better lung function (FEV1%pred. 73.6±29.9 vs. 62.7±29.5, p<0.001) females reported a similar symptom burden (CAT 13.4±9.5 vs. 12.5±8.9, p=ns) and exacerbation frequency (at least one in the previous year 30% vs. 26%, p=ns) compared to males. In multivariate analyses, female sex was an independent risk factor for exacerbations in the previous year OR 1.6 p=0.001 in addition to smoking history, COPD, asthma and bronchiectasis and was also identified as risk factors for symptom burden (CAT≥10) OR 1.4 p=0.014 besides age, BMI, COPD and smoking history.

  Conclusion: Men had higher rates of COPD and liver disease, women were more likely to have bronchiectasis. Women's higher symptom burden and exacerbation frequency suggest they may need tailored treatment approaches.

  Copyright © 2024 The Author(s). Published by Elsevier España, S.L.U. All rights reserved.

• Gelatinous Pleural Fluid With Mesothelioma. M. Kaous, L. Bashoura, S.A. Faiz. 2021;57(8):543. PubMed · Publisher

2010s

• Asbestos and the law. G. Poyatos, C. Diego Roza. 2017;53(1):5-6. In English, Spanish. Historical article PubMed · Publisher

• Deferred Locoregional Recurrence of Pleural Mesothelioma. F.J. García-Gómez, T. García-Manrique, J. Castro-Montaño. 2017;53(10):584-585. In English, Spanish. Case report PubMed · Publisher

• Malignant pleural mesothelioma in a young adult with no known exposure to asbestos. Can asbestos exposure be truly ruled out?. J. Ferrer, J. Sampol, M.J. Cruz. 2017;53(8):469. In English, Spanish. Letter · Comment PubMed · Publisher

• Recommendations for the Diagnosis and Management of Asbestos-Related Pleural and Pulmonary Disease. C. Diego Roza, M.J. Cruz Carmona, R. Fernández Álvarez, et al. 2017;53(8):437-442. In English, Spanish. Guideline PubMed · Publisher

  Abstract

  Asbestos is the term used for a set of mineral silicates that tend to break up into fibers. Its use has been associated with numerous diseases affecting the lung and pleura in particular, all of which are characterized by their long period of latency. Asbestos, moreover, has been recognized by the WHO as a Group IA carcinogen since 1987 and its use was banned in Spain in 2002. The publication in 2013 of the 3rd edition of the specific asbestos health monitoring protocol, together with the development of new diagnostic techniques, prompted the SEPAR EROM group to sponsor publication of guidelines, which review the clinical, radiological and functional aspects of the different asbestos-related diseases. Recommendations have also been made for the diagnosis and follow-up of exposed patients. These recommendations were drawn up in accordance with the GRADE classification system.

  Copyright © 2017 SEPAR. Publicado por Elsevier España, S.L.U. All rights reserved.

• Utility of Bronchoalveolar Lavage for the Diagnosis of Asbestos-Related Diseases. M.J. Cruz, V. Curull, L. Pijuan, et al. 2017;53(6):318-323. In English, Spanish. PubMed · Publisher

  Abstract

  Introduction: Bronchoalveolar lavage (BAL) analysis has been proposed as an objective technique for confirming asbestos exposure. However, the reliability and diagnostic yield of this procedure has not been studied in Spain. The aim of this study was to assess the usefulness of the analysis of asbestos bodies (AB) in bronchoalveolar lavage (BAL) for the diagnosis of asbestos-related diseases (ARD).

  Methods: BAL samples from 72 patients (66 male, mean age 66 years) undergoing bronchoscopy were analyzed. Lung tissue from 23 of these patients was also analyzed. Asbestos exposure was assessed by anamnesis and a review of the patient's medical records. BAL and lung samples were processed and AB count was determined by light microscopy. The accepted threshold value to diagnose asbestos-related diseases was 1 AB/ml BAL or 1000 AB/gr dry tissue.

  Results: Thirty-nine patients reported exposure to asbestos. Of these, 13 (33%) presented AB values above 1 AB/ml BAL. In the 33 non-exposed patients, 5 (15%) presented AB values above 1 AB/ml BAL. There was a significant difference between the AB levels of exposed and non-exposed patients (P=.006). The ROC curve showed that a value of 0.5 AB/ml BAL achieved the most satisfactory sensitivity, 46%, and a specificity of 83%. The correlation between AB levels in BAL and lung was 0.633 (P=.002).

  Conclusions: BAL study provides objective evidence of exposure to asbestos. The good correlation between the AB counts in BAL and lung tissue indicates that both techniques are valid for the analysis of asbestos content.

  Copyright © 2016 SEPAR. Publicado por Elsevier España, S.L.U. All rights reserved.

• Utility of CEA and CA 15-3 measurements in non-purulent pleural exudates in the diagnosis of malignancy: A single-center experience. J.M. Porcel, C. Civit, A. Esquerda, et al. 2017;53(8):427-431. In English, Spanish. PubMed · Publisher

  Abstract

  Objective: To establish the diagnostic accuracy of pleural fluid (PF) CEA and CA 15-3 in identifying malignancy, and to determine the additional value of these markers in patients with malignant pleural effusions (MPEs) with false negative results from cytological fluid examination.

  Methods: PF concentrations of CEA and/or CA 15-3 were determined in 1,575 patients with non-purulent exudates, 549 of whom had confirmed MPEs, 284 probable MPEs, and 742 benign effusions. Tumor marker cut-off points were set to ensure 100% specificity for malignant effusion.

  Results: The 41, 40 and 60% of MPE patients had high PF levels of CEA (>45ng/mL), CA 15-3 (>77 UI/l) or both, respectively. These percentages were 30, 19 and 41% in MPEs with positive pleural biopsy and negative PF cytology; and 24, 13 and 35% in clinical MPEs without histocytological confirmation. Tumor markers were of no value in lymphomas and mesotheliomas. The area-under-the-curve for CEA was 0.819 (95% CI: 0,793-0,845) and for CA 15-3, it was 0.822 (95% CI: 0,796-0,847). The use of tumor markers compared to cytology alone, increased the diagnosis of malignancy by 14%.

  Conclusions: Measurements of PF CEA and CA 15-3 may complement pleural cytology in the identification of MPEs.

  Copyright © 2017 SEPAR. Publicado por Elsevier España, S.L.U. All rights reserved.

• Malignant pleural mesothelioma in a young adult with no known exposure to asbestos. E. Espinosa Muñoz, D. Ramírez Ocaña, A.L. Gutiérrez Cardo. 2016;52(12):615-616. In English, Spanish. Case report PubMed · Publisher

• The possible role of asbestos exposure in the pathogenesis of a thoracic non-Hodgkin lymphoma. C. Bianchi, T. Bianchi. 2016;52(9):490-1. In English, Spanish. Case report PubMed · Publisher

• Diagnosis and treatment of malignant pleural mesothelioma. F. Rodríguez Panadero. 2015;51(4):177-84. In English, Spanish. Review PubMed · Publisher

  Abstract

  There are three major challenges in the diagnosis of malignant pleural mesothelioma: mesothelioma must be distinguished from benign mesothelial hyperplasia; malignant mesothelioma (and its subtypes) must be distinguished from metastatic carcinoma; and invasion of structures adjacent to the pleura must be demonstrated. The basis for clarifying the first two aspects is determination of a panel of monoclonal antibodies with appropriate immunohistochemical evaluation performed by highly qualified experts. Clarification of the third aspect requires sufficiently abundant, deep biopsy material, for which thoracoscopy is the technique of choice. Video-assisted needle biopsy with real-time imaging can be of great assistance when there is diffuse nodal thickening and scant or absent effusion. Given the difficulties of reaching an early diagnosis, cure is not generally achieved with radical surgery (pleuropneumonectomy), so liberation of the tumor mass with pleurectomy/decortication combined with chemo- or radiation therapy (multimodal treatment) has been gaining followers in recent years. In cases in which surgery is not feasible, chemotherapy (a combination of pemetrexed and platinum-derived compounds, in most cases) with pleurodesis or a tunneled pleural drainage catheter, if control of pleural effusion is required, can be considered. Radiation therapy is reserved for treatment of pain associated with infiltration of the chest wall or any other neighboring structure. In any case, comprehensive support treatment for pain control in specialist units is essential: this acquires particular significance in this type of malignancy.

  Copyright © 2014 SEPAR. Published by Elsevier Espana. All rights reserved.

• Jejunal Perforation by Metastasis of Malignant Pleural Mesothelioma. M.I. Navarro García, A. Sánchez Pérez, J.L. Vázquez Rojas. 2015;51(7):366-7. In English, Spanish. Case report · Letter PubMed · Publisher

  Summary

  This letter to the editor, written in Spanish by surgeons in Cartagena, Murcia, Spain, reported a case of jejunal perforation caused by metastasis of malignant pleural mesothelioma. The authors noted that asbestos is the main factor implicated in this tumour, which usually stays local in the affected side of the chest; metastatic disease is uncommon and gastrointestinal complications from metastases are rare. The patient was a 67-year-old man who had undergone radical pleuropneumonectomy with lymphadenectomy in July 2010 for malignant pleural mesothelioma (T3N2M0), followed by adjuvant chemotherapy. In August 2011 he came to the emergency department with sudden abdominal pain of 4 hours' duration and signs of peritoneal irritation. Laboratory tests were normal. Abdominal CT showed pneumoperitoneum and wall thickening of a short segment of jejunum. Emergency surgery found acute purulent peritonitis from a single jejunal perforation over an ischaemic plaque. The bowel segment was resected and rejoined. Pathology showed metastasis of epithelioid malignant mesothelioma in the bowel wall and in 2 lymph nodes. Recovery was satisfactory and chemotherapy was started. A Medline review (1974-2013) found 4 reported cases with small-bowel involvement and one earlier case presenting as acute jejunal perforation, making this the second acute presentation. The authors concluded that small-bowel metastasis should be considered in patients with a history of this cancer who have acute abdominal pain, occult blood in the stool or intermittent, non-specific abdominal pain.

  PubMed has no abstract for this study, and the article doesn't print one. We wrote this summary from the full article with the help of AI. It is not the authors' wording.

• Long-term Outcome of Patients With Undiagnosed Pleural Effusion. G. Gunluoglu, A. Olcmen, M.Z. Gunluoglu, et al. 2015;51(12):632-6. In English, Spanish. PubMed · Publisher

  Abstract

  Introduction: The cause of exudative pleural effusion cannot be determined in some patients. The longterm outcomes of patients with undiagnosed pleural effusion were analyzed.

  Methods: Patients with exudative pleural effusion whose diagnostic procedures included pleural biopsy using video-assisted thoracoscopic surgery carried out between 2008 and 2012 were evaluated retrospectively. Patients diagnosed with non-specific pleuritis were included. Fifty-three patients with available follow-up data were included in the study.

  Results: Forty men and 13 women (mean age 53.9±13.9 years) were included. Median follow-up time was 24 months. No diagnosis was given in 27 patients (51%), and a clinical diagnosis was given in 26 patients (49%) during the follow-up period. Malignant disease (malignant mesothelioma) was diagnosed in 2 (3.7%) patients. Other diseases were parapneumonic effusion in 12, congestive heart failure in 8, and miscellaneous in 4 patients. Volume of effusion at the time of initial examination and re-accumulation of fluid after video-assisted thoracoscopic surgery were associated with malignant disease (P=.004 and .0001, respectively).

  Conclusion: Although the probability is low, some patients with exudative pleural effusion undiagnosed after pleural biopsy via video-assisted thoracoscopic surgery may have malignant disease. Patients with an initially large volume of effusion that re-accumulates after examination should be closely monitored.

  Copyright © 2014 SEPAR. Published by Elsevier Espana. All rights reserved.

• Status of the ban on asbestos use in Spain and Latin America. R.A. Accinelli Tanaka, L.M. López Oropeza. 2015;51(3):152. In English, Spanish. Letter PubMed · Publisher

• Etiology of pleural effusions: analysis of more than 3,000 consecutive thoracenteses. J.M. Porcel, A. Esquerda, M. Vives, et al. 2014;50(5):161-5. In English, Spanish. PubMed · Publisher

  Abstract

  Objective: To investigate the etiology of pleural effusions (PE) in adults and the accuracy of pleural fluid (PF) cytology and cultures in malignant and infectious PE, respectively.

  Patients And Methods: Retrospective analysis of all consecutive patients with PE undergoing diagnostic thoracentesis during the last 19 years in a university hospital.

  Results: The leading causes of PE among the 3,077 patients were: cancer (27%), heart failure (21%), pneumonia (19%), tuberculosis (9%), abdominal surgery (4%), pericardial diseases (4%) and cirrhosis (3%). Tuberculosis was the most common etiology in patients <34 years of age (52%), whereas heart failure predominated in octogenarians (45%). The most common primary tumors in malignant PE were lung (37%) and breast (16%). The overall accuracy of PF cytology was 59%, although it was significantly lower in mesotheliomas (27%) and squamous cell lung cancer (25%). In infectious PE, only 30% of cultures yielded positive results, a percentage which increased two-fold (66%) in purulent fluids (empyemas). Viridans streptococci were the most commonly isolated pathogens (25.5%). The sensitivity of solid media cultures of PF for Mycobacterium tuberculosis was low (18.5%).

  Conclusions: Three-quarters of patients with PE in whom a diagnostic thoracentesis was indicated had cancer, heart failure, pneumonia or tuberculosis. PF cytology and cultures give false negative results in a significant number of cases.

  Copyright © 2013 SEPAR. Published by Elsevier Espana. All rights reserved.

• Deciduoid pleural mesothelioma in an adolescent. E. Arango-Tomás, F.J. Algar-Algar, A. Salvatierra Velázquez. 2013;49(5):218-9. In English, Spanish. Case report · Letter PubMed · Publisher

  Summary

  This letter to the editor described a case of deciduoid pleural mesothelioma, a rare variant of epithelioid mesothelioma, in a 17-year-old patient. The authors considered the case unusual because of the patient's age and absence of prior history. The patient had a persistent non-productive cough that did not improve with antibiotics and analgesics. Blood tests showed microcytic hypochromic anaemia, thrombocytosis and elevated C-reactive protein. CT showed a 9 cm heterogeneous solid mass in the left upper lobe. MRI showed that the mass was extrapulmonary, arose from the pleura, infiltrated the mediastinum and partly surrounded the origin of the left subclavian artery. PET showed a maximum SUV of 8.55, with no mediastinal uptake. Fine-needle aspiration found malignant cells. Surgical biopsy confirmed infiltration of the mediastinum, aortic arch and aortopulmonary window. On pathology the large epithelial cells were positive for cytokeratin AE1/AE3, calretinin, WT-1 and EMA, consistent with deciduoid epithelial pleural mesothelioma. The IMIG stage was T3-N0-M0 (stage III). Extrapleural pneumonectomy was ruled out, and the patient received cisplatin and pemetrexed, with survival of 21 months at the time of writing. The authors noted that 23 pleural cases had been published, that 68% of patients die within the first year, and that this subtype is not related to asbestos exposure. They concluded that cytoreduction can be offered to patients without nodal involvement, with neoadjuvant cisplatin and pemetrexed recommended in advanced stages.

  PubMed has no abstract for this study, and the article doesn't print one. We wrote this summary from the full article with the help of AI. It is not the authors' wording.

• Pleural mesothelioma secondary to radiotherapy: a rare association. T. Lourido-Cebreiro, V. Leiro-Fernández, A. Fernández-Villar. 2012;48(12):482-3. In English, Spanish. Case report · Letter PubMed · Publisher

  Summary

  This letter to the editor described a case of malignant pleural mesothelioma that the authors attributed to earlier radiotherapy. A 60-year-old woman was referred to an outpatient pleural unit in Vigo, Spain, with a left pleural effusion, 8 weeks of pleuritic left chest pain, dry cough and general deterioration. She had never smoked and worked as a housewife. Neither she nor her family had environmental or occupational exposure to toxic agents, including asbestos, and she did not live near asbestos-related industries. Ten years earlier she had been treated for infiltrating ductal breast carcinoma with mastectomy, chemotherapy and radiotherapy. Pleural fluid was a lymphocytic exudate with negative cytology. An ultrasound-guided Abrams needle biopsy showed no abnormality. PET-CT showed uptake in the left apical pleura (maximum SUV 6.8) and the left basal subpleural area (SUV 3.8). CT-guided fine-needle aspiration of the most active area showed atypical mesothelial proliferation. Video-assisted thoracoscopic pleural biopsy confirmed epithelial-type malignant pleural mesothelioma. In a literature review, the authors identified 6 reported cases of radiation-induced mesothelioma after breast cancer radiotherapy. The interval from radiation to mesothelioma was 10 to 30 years and the mean age at presentation was 55 years. By comparison, asbestos-related mesothelioma usually appears 30 to 40 years after exposure and in older patients. The authors concluded that this diagnosis should be considered in patients with pleural thickening suggestive of tumour and a history of chest radiotherapy. They also concluded that a guideline-based diagnostic protocol was useful.

  PubMed has no abstract for this study, and the article doesn't print one. We wrote this summary from the full article with the help of AI. It is not the authors' wording.

Browse every journal in the library or the library by type of article, or return to medical research.